Email updates

Keep up to date with the latest news and content from BMC Pharmacology and Toxicology and BioMed Central.

Open Access Research article

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study

Andrew Spencer1*, Andrew Roberts2, Nola Kennedy1, Christina Ravera3, Serge Cremers3, Sanela Bilic3, Terry Neeman4, Michael Copeman5, Horst Schran3 and Kevin Lynch5

Author Affiliations

1 Department of Haematology and Bone Marrow Transplantation, The Alfred Hospital, Prahan, Victoria, Australia

2 Department of Haematology, Royal Melbourne Hospital, Parkville, Victoria, Australia

3 Department of Clinical Pharmacology, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA

4 Covance Pty. Ltd., Canberra, ACT, Australia

5 Novartis Pharmaceuticals Australia Pty. Ltd., 54 Waterloo Rd, North Ryde NSW 2113, Australia

For all author emails, please log on.

BMC Clinical Pharmacology 2008, 8:2  doi:10.1186/1472-6904-8-2

Published: 31 March 2008

Abstract

Background

Cases of impaired renal function have been reported in patients who had been treated with both zoledronic acid and thalidomide for myeloma. Hence, we conducted a safety study of zoledronic acid and thalidomide in myeloma patients participating in a trial of maintenance therapy.

Methods

Twenty-four patients who were enrolled in a large randomized trial of thalidomide vs no thalidomide maintenance therapy for myeloma, in which all patients also received zoledronic acid, were recruited to a pharmacokinetic and renal safety sub-study, and followed for up to 16 months.

Results

No significant differences by Wilcoxon rank-sum statistic were found in zoledronic acid pharmacokinetics or renal safety for up to 16 months in patients randomized to thalidomide or not.

Conclusion

In myeloma patients receiving maintenance therapy, the combination of zoledronic acid and thalidomide appears to confer no additional renal safety risks over zoledronic acid alone.